Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
(NASDAQ:ONCT), SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T […]